1. Pink Sheet
  2. >>Pathways & Standards

Califf Hints At Labeling Changes For Opioids And Chronic Pain

 
• By Sarah Karlin-Smith

Califf also said the agency is open to endpoints other than abstinence for new opioid use disorder treatments at the fourth annual NIH HEAL Initiative Investigator Meeting. 

person in pain
The FDA Commissioner Highlighted a New CDC Report Citing ‘No Evidence’ Of Chronic Opioid Benefit When Discussing Potential Labeling Changes. • Source: Shutterstock

US Food and Drug Administration Commissioner Robert Califf offered subtle hints at a recent National Institutes of Health meeting that the agency may eventually try to curtail long-term opioid use through drug labeling.

“It’s well known that we’re looking closely at the labeling of chronic opioids at this point,” Califf said 22 February at the NIH Helping to End Addiction Long-term (HEAL) Initiative investigator meeting. “I can’t say what we’re going to do or when we’re going to do it. I’m not allowed to do that

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By Vibha Sharma

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

US FDA Waiting On Guidance Agenda Future As HHS Seeks Regulation Cuts

 
• By Derrick Gingery

The FDA continues to wait for a decision on whether its priority guidances will be published as HHS asks the public for potential regulation cuts to fulfill President Trump’s executive order.